Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Labeled Immunoassays and Clinical Medicine》 2016-12
Add to Favorite Get Latest Update

Expression and Immuntherapy Prospect of MAGE-A Family and NY-ESO-1 in Breast Cancer

LI Feng-lian;SANG Mei-xiang;The Fifth Hospital of Hengshui;Department of Immunology,Tumor Research Institute,Fourth Hospital of Hebei Medical University;  
The tumor immune therapy based on specific tumor antigen has become a newmode of treatment for breast cancer while cancer testicular antigen( CTA) has been booming research on tumor immune therapy.As important members of CTA family,MAGE-A family and NY-ESO-1 are playing a crucial role in the diagnosis,treatment,prognosis and other aspects of breast cancer. Different members of the MAGE-A family have different positive expressions in breast cancer tissues,whose expression mechanism may be related to DNA methylation and histone acetylation. Currently the research of MAGE-A vaccine is still in its infancy,and its application has some limitations. It is believed that the activation of MAGE-A expression by the methylation of drugs can increase the immunogenicity of MAGE-A,thus enhancing the efficacy of immunotherapy. NY-ESO-1 can be expressed positively in different tumor types,and it serves as an important index to judge tumor prognosis. Gene methylation may be a mechanism to regulate the expression of NY-ESO-1 in tumor. A variety of vaccines based on NY-ESO-1 have entered their clinical research stage successively. In conclusion,MAGE-A and NY-ESO-1 are more likely to be ideal targets for immunotherapy nowand in the future.
【CateGory Index】: R737.9;R730.43
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved